申请人:Eli Lilly and Company
公开号:US05629290A1
公开(公告)日:1997-05-13
Provided are pharmaceutical formulations, and methods of inhibiting fungal and parasitic activity using a compound of formula I ##STR1## where: R', R", R'", R.sup.x1, R.sup.x2, R.sup.y1, R.sup.y2, R.sup.y3, R.sup.y4, and R.sup.0 are as defined hereinabove; and R.sup.2 is ##STR2## R.sup.3 is ##STR3## R.sup.3a is C.sub.1 -C.sub.6 alkyl or C.sub.1 -C.sub.6 alkoxy; R.sup.3b and R.sup.3c are independently phenyl or naphthyl; R.sup.3d is C.sub.1 -C.sub.12 alkyl, C.sub.1 -C.sub.12 alkoxy or --O --(CH.sub.2).sub.m -[O--(CH.sub.2).sub.n ].sub.p --O--(C.sub.1 -C.sub.12 alkyl); m is 2, 3 or 4; n is 2, 3 or 4; p is 0 or 1; or a pharmaceutically acceptable salt thereof.
提供了药物配方和使用式I化合物来抑制真菌和寄生虫活性的方法。其中,式中的R'、R"、R'"、R.sup.x1、R.sup.x2、R.sup.y1、R.sup.y2、R.sup.y3、R.sup.y4和R.sup.0的定义如上所述;R.sup.2为##STR2##;R.sup.3为##STR3##;R.sup.3a为C.sub.1-C.sub.6烷基或C.sub.1-C.sub.6烷氧基;R.sup.3b和R.sup.3c独立地为苯基或萘基;R.sup.3d为C.sub.1-C.sub.12烷基、C.sub.1-C.sub.12烷氧基或--O--(CH.sub.2).sub.m-[O--(CH.sub.2).sub.n].sub.p--O--(C.sub.1-C.sub.12烷基);m为2、3或4;n为2、3或4;p为0或1;或其药学上可接受的盐。